Fragmin Patient Assistance - Rx Outreach

Phone: 1-877-318-9557

Fax: 1-888-430-9818

Monday - Friday 7:00 AM to 5:30 PM CST


Coverage Policy

The information displayed below pertains specifically to the Physician Office setting of care. For information tailored to the Hospital Outpatient setting or Pharmacy setting, please select the appropriate tab to the right. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. See below

Most third-party payors, including HMO plans, managed care organizations, indemnity plans and others provide coverage for FRAGMIN®.  However, specific coverage requirements and restrictions depend on a patient’s benefits and will vary based on plan type and provider site of service.   Some payors have established formal published policies, but the lack of a published policy from a particular payor does not mean that FRAGMIN® is not covered by that payor.  In addition, commercial payors may cover FRAGMIN® as a medical benefit, a pharmacy benefit, or both. Each benefit is administered separately and may have different deductible, copayment and/or coinsurance structures. Some commercial insurers may apply coverage and utilization restrictions such as prior authorization or quantity limit edits to FRAGMIN®.

For more information on commercial payor specific coverage of FRAGMIN®, contact your health plan.

Payor Reimbursement

Commercial payor reimbursement for FRAGMIN® may be based on a percent mark-up of Average Sales Price (ASP) similar to Medicare reimbursement methodologies.  Payment may also be based on a percent mark-up or mark-down of Average Wholesale Price (AWP) or Wholesale Acquisition Cost (WAC). 

Administration Services

Commercial payor reimbursement for physician-related FRAGMIN® drug administration services may be based on a common fee schedule similar to the Medicare reimbursement methodology for physician services or other contracted rates.

Indications

FRAGMIN® is a low molecular weight heparin (LMWH) indicated for:

Limitations of Use

Important Safety Information

WARNING: SPINAL/EPIDURAL HEMATOMA

Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:

  • Use of indwelling epidural catheters
  • Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants
  • A history of traumatic or repeated epidural or spinal punctures
  • A history of spinal deformity or spinal surgery Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.

Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis [see Warnings and Precautions and Drug Interactions].

For more information about FRAGMIN, please see Full Product Information.



Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.

This information is intended for use by our healthcare professionals in the United States only. Eisai Inc. recognizes the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States. This site contains information about products that may have different product labeling in different countries.

FRAGMIN® is a registered trademark of Pfizer Heal AB and is licensed to Eisai Inc.

Distributed and marketed by Eisai Inc. CORP74CR8 ©2012 Eisai Inc. All rights reserved.

This site was last modified on : April 2, 2012 at 11:40am ET